Claire Davies Profile picture
Diabetes and Endocrinology Specialist Pharmacist 💊 @UKCPADiabetes Committee Member. AVMO. Serial raspberry eater. Sports addict🎾. NUFC fan⚽️🙌. Geordie 👍

Nov 16, 2022, 19 tweets

Lots and lots of #lipids today @diabetespc this time with @PNewlandJones covering the fundamentals we all need to know for #PLWD

Once again standing room only!
And managed to catch his eye to say 😀 for the camera 📸

Phil explaining how lipids have become unnecessarily complicated

We have gone from one medicine and one back up to multiple options for lipid management

Today going to take things back to fundamentals

How complicated lipids can be in one diagram 🖼️

Take away point: multiple mechanisms to lower lipids, work on different parts of the pathway

Lipoproteins broken down by size

- LDL will move cholesterol around the body
- Chylomicrons - smaller, risk of causing pancreatitis

What’s in a blood? What’s in a lipid profile?

So what tests do we need?

Initial sample does NOT need to be fasting. Make the most of every visit. Test if able.

Primary Prevention:

- don’t use QRISK for T1DM

- for males, T2DM over 51 QRISK will be over 10%
- for females, T2DM over 58 QRISK will be over 10%

Titrate up doses until getting a reduction of 40% of baseline

Causes of raised cholesterol

Important to take full history

Managing dyslipidaemia in DM

Secondary prevention:

Work backwards, start high and reduce as able

Ezetimibe:
- far lower CV benefits than a statin - particularly CV end points/events

PCSK9:
- rapidly recycle and clear lipid receptors

- imagine a snooker 🎱 table, more pockets
- increase uptake and recycling process

- tight criteria
- potent medicines - can see big drops

Negatives:
- cost and access

Bempedoic acid:
- work similarly to statins
- good for true statin intolerance patients

Inclisiran:
- works similarly to PCSK9 inhibitors
- limited outcome data

Statins:

- if you reduce LDL by 1mmol/L with statins you reduce CV risk by 20%

Is intolerance a no-cebo effect? As myopathy figures in RCTs are a lot less than reported in practice

Statin intolerance:
- simplified pathway
- washout period (longer washout if high CK)
- then re challenge
- if symptoms persist before rechallenge unlikely the cause was the statin

Consider potent statins once or twice a week E.g rosuvastatin

Lipid medicines compared by potency:

Summary slides:

Share this Scrolly Tale with your friends.

A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.

Keep scrolling